Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- M3, NBI Pair Up to Develop AI-Powered Diagnostic Support for Lung Diseases
December 9, 2020
- Sanofi’s Kawagoe Site Aims to Join World’s Top 10% Productivity List by 2022-End
December 8, 2020
- China’s Bidding System at National Hospitals Hurting Japan Firms' Off-Patent Drug Sales; Eisai, Kaken, Santen Suffer Drops
December 8, 2020
- Hisamitsu’s NSAIDs Patch Hits Primary Goals in 2 PIII Studies
December 8, 2020
- Japan Ethical Drug Sales Down 3.3% in October: Crecon
December 8, 2020
- Maribavir Hits Primary Goal for Post-Transplant CMV Infection: Takeda
December 8, 2020
- Kobayashi Kako Launches Another Recall for Itraconazole, Class II This Time
December 8, 2020
- Astellas in Oncolytic Virus Deal with KaliVir
December 8, 2020
- Astellas, Viatris Wind Up Japan Celecox Copromotion at December-End
December 8, 2020
- Kyle Tattle to Take Reins of MSD Japan from January
December 8, 2020
- Teijin Pharma’s Spasticity Med Xeomin Now Available
December 7, 2020
- Keytruda Top Seller for 4 Months Running: Encise
December 7, 2020
- Ex-Janssen Exec Rami Suzuki to Lead Ferring Japan
December 7, 2020
- Kobayashi Kako Recalls Itraconazole over Hypnotic Contamination; Side Effects Confirmed
December 7, 2020
- 26 Japan Drug Makers Barely Avoid Revenue Decline in H1 FY2020 Despite Price Cuts, COVID-19: Tally
December 4, 2020
- Sandoz to Discontinue Filgrastim Biosimilars; Late Market Entry a Factor
December 4, 2020
- 2 More Soft Bag Products Recalled Over Flawed Testing at Kyowa CritiCare
December 3, 2020
- Telomelysin Triplet Enters Japan PI for HCC: Oncolys
December 3, 2020
- Janssen Files SC Injection of Darzalex/Vorhyaluronidase Alfa for AL Amyloidosis in Japan
December 3, 2020
- Crysvita Now Available for Self-Injection in Japan: Kyowa Kirin
December 2, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…